Despite the challenges involved, leveraging PD-1/PD-L1 pathway modulation as an MS treatment holds significant potential benefits and could result in a more precise and efficient therapeutic approach with fewer adverse effects compared to current treatments. This evidence concerns the gene PDCD1 and myeloid sarcoma.